"hybryte™ use in early-stage cutaneous t-cell lymphoma" published in frontiers in drug discovery

Hybryte™ has potential to address a critical gap in treatment of early-stage ctcl princeton, n.j. , dec. 1, 2023 /prnewswire/ -- soligenix, inc. (nasdaq: sngx) (soligenix or the company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that an article describing the potential use of hybryte™ in the treatment of cutaneous t-cell lymphoma (ctcl) has been published in frontiers in drug discovery.
SNGX Ratings Summary
SNGX Quant Ranking